BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37990343)

  • 1. Genitourinary cancers updates: highlights from ASCO 2023.
    Qin Q; Sheffield H; Taasan SM; Wang AZ; Zhang T
    J Hematol Oncol; 2023 Nov; 16(1):112. PubMed ID: 37990343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Landscape of Immunotherapy in Genitourinary Malignancies.
    Alhalabi O; Rafei H; Bilen MA; Shah AY
    Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel immunotherapies in GU malignancies.
    Drakaki A; McDermott DF
    Curr Oncol Rep; 2013 Jun; 15(3):224-31. PubMed ID: 23519772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
    Bigot F; Bonnet C; Massard C
    Bull Cancer; 2017 Apr; 104(4):370-379. PubMed ID: 28237355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inside the 2015 ASCO Genitourinary Cancers Symposium.
    Santoni M; Massari F; Iacovelli R; Ciccarese C; Verri E; Burattini L; Montironi R; Nolè F; Tortora G; Cascinu S
    Future Oncol; 2015; 11(13):1859-62. PubMed ID: 26161923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data.
    Nathan P; Rajeh A; Noor M; Boldt G; Fernandes R
    Curr Oncol; 2024 Apr; 31(4):2316-2327. PubMed ID: 38668075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genitourinary Cancer: Updates on Treatments and Their Impact on the Kidney.
    Orozco Scott P; Deshpande P; Abramson M
    Semin Nephrol; 2022 Nov; 42(6):151344. PubMed ID: 37172546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
    Yu J; Wu S; Li R; Jiang Y; Zheng J; Li Z; Li M; Xin K; Guan X; Li S; Chen X
    J Hematol Oncol; 2023 Jul; 16(1):85. PubMed ID: 37507780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Landscape of Immunotherapy in Genitourinary Malignancies.
    Ravindranathan D; Alhalabi O; Rafei H; Shah AY; Bilen MA
    Adv Exp Med Biol; 2021; 1342():143-192. PubMed ID: 34972965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in genitourinary malignancies.
    Wattenberg MM; Fong L; Madan RA; Gulley JL
    Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel immunotherapy combinations for genitourinary cancers.
    Al Harthy M; Redman J; Madan RA
    Expert Opin Biol Ther; 2020 Mar; 20(3):253-262. PubMed ID: 31914333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in genitourinary neoplasia.
    Droller MJ
    J Urol; 1985 Jan; 133(1):1-5. PubMed ID: 2578065
    [No Abstract]   [Full Text] [Related]  

  • 13. Biologic tools to personalize treatment in genitourinary cancers.
    Bracarda S; Sisani M; Del Buono S; Ishiwa O; Montagnani F;
    Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e42-8. PubMed ID: 21232974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma.
    Iacovelli R; Cannella MA; Ciccarese C; Astore S; Foschi N; Palermo G; Tortora G
    Expert Rev Anticancer Ther; 2021 Nov; 21(11):1203-1206. PubMed ID: 34482771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activities and accomplishments of the cancer and leukemia group B genitourinary committee.
    Small EJ; Halabi S; Kantoff P; D'Amico A; Stadler W; Kelley WK; Mohler J; Bajorin D; Vogelzang NJ
    Clin Cancer Res; 2006 Jun; 12(11 Pt 2):3596s-600s. PubMed ID: 16740791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive Immunity in Genitourinary Cancers.
    Koti M; Bivalacqua T; Black PC; Cathomen T; Galsky MD; Gulley JL; Ingersoll MA; Kamat AM; Kassouf W; Siemens DR; Gao J
    Eur Urol Oncol; 2023 Jun; 6(3):263-272. PubMed ID: 37069029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current State of Cell Therapies for Genitourinary Malignancies.
    Alkhouli MA; Bazargan S; Pilon-Thomas S; Poch M; Chahoud J
    Cancer J; 2022 Jul-Aug 01; 28(4):294-300. PubMed ID: 35880939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy advances in uro-genital malignancies.
    Ratta R; Zappasodi R; Raggi D; Grassi P; Verzoni E; Necchi A; Di Nicola M; Salvioni R; de Braud F; Procopio G
    Crit Rev Oncol Hematol; 2016 Sep; 105():52-64. PubMed ID: 27372200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Overview of Emerging Immunotargets of Genitourinary Tumors.
    Montironi R; Santoni M; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Scarpelli M
    Curr Drug Targets; 2016; 17(7):750-6. PubMed ID: 26648079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.